abbrevi
dc
dendrit
cell
fc
gamma
receptor
fibrinogenlik
protein
fred
fibrinogenrel
domain
hbv
hepat
b
viru
hcv
hepat
c
viru
il
interleukin
mhc
major
histocompat
complex
murin
hepat
viru
strain
svr
sustain
virolog
respons
treg
cell
regulatori
cell
chronic
hepat
c
viru
hcv
infect
lead
caus
liver
diseas
worldwid
remain
common
indic
liver
transplant
current
standard
care
lead
sustain
viral
respons
roughli
treat
patient
best
furthermor
antivir
therapi
expens
prolong
associ
seriou
sideeffect
evid
suggest
poor
respons
treatment
may
result
suppress
antivir
immun
due
presenc
increas
number
activ
regulatori
cell
treg
cell
other
recent
identifi
fibrinogenlik
protein
put
effector
treg
cell
account
suppress
function
bind
fc
gamma
receptor
experiment
model
fulmin
viral
hepat
laboratori
show
increas
plasma
level
preand
postvir
infect
predict
suscept
sever
diseas
moreov
treatment
antibodi
fulli
protect
suscept
anim
lethal
viru
adopt
transfer
wildtyp
treg
cell
resist
anim
acceler
mortal
postinfect
patient
hcv
infect
plasma
level
express
liver
correl
cours
sever
diseas
collect
studi
suggest
may
use
biomark
predict
diseas
progress
hcv
patient
logic
target
develop
novel
therapeut
approach
treatment
patient
hcv
infect
hepat
c
viru
hcv
infect
lead
caus
liver
diseas
estim
million
peopl
infect
worldwid
untreat
inflammatori
respons
viru
promot
hepat
fibrosi
develop
cirrhosi
may
complic
hepatocellular
cancer
hcc
result
hcv
infect
becom
common
indic
liver
transplant
unfortun
hcv
reinfect
graft
occur
univers
associ
aggress
cours
proport
patient
lead
graft
cirrhosi
recipi
within
year
therefor
surviv
hcvposit
liver
transplant
recipi
overal
significantli
lower
hcvneg
patient
goal
hcv
treatment
prevent
hepat
cirrhosi
hepatocellular
cancer
extrahepat
complic
perman
erad
viru
present
standard
care
treat
chronic
hcv
combin
weekli
subcutan
inject
pegyl
ribavirin
rbv
week
depend
viral
genotyp
treatment
need
prolong
month
complianc
necess
add
treatment
expens
associ
signific
sideeffect
rate
sustain
viral
respons
svr
follow
therapi
best
overal
present
number
host
viral
factor
associ
respons
therapi
includ
race
viral
genotyp
alcohol
intak
liver
histolog
amount
steatosi
stage
fibrosi
genet
divers
host
contribut
outcom
hcv
infect
antivir
treatment
sequenc
human
genom
togeth
develop
new
technolog
gene
express
profil
highthroughput
protein
analysi
provid
opportun
rapid
accur
character
gene
express
tissu
detect
individu
host
genet
polymorph
exampl
group
recent
identifi
consist
pattern
gene
express
pretreat
liver
biopsi
predict
treatment
respons
identif
biomark
predict
antivir
treatment
respons
would
provid
import
diagnost
reagent
manag
hcv
may
allow
develop
novel
therapeut
patient
hcv
infect
innat
adapt
immun
respons
import
viral
clearanc
innat
immun
number
innat
effector
cell
cytokin
shown
import
clearanc
hcv
infect
natur
killer
nk
cell
play
key
role
innat
antivir
immun
respons
hcv
addit
product
type
interferon
ifn
import
firstlin
defens
hcv
infect
nonstructur
protein
proteas
hcv
shown
impair
ifn
product
ifn
respons
would
contribut
inabl
mount
effect
immun
respons
hcv
adapt
immun
robust
cell
respons
associ
clearanc
hcv
impair
cell
respons
known
associ
chronic
hcv
patient
spontan
recov
hcv
infect
maintain
virusspecif
cell
respons
readili
detect
blood
respons
contribut
control
andor
clearanc
hcv
shown
nonhuman
primat
model
hcv
infect
model
deplet
either
cell
prior
challeng
hcv
lead
chronic
infect
high
viral
titer
patient
chronic
hcv
typic
display
narrowli
focus
weak
hcvspecif
cell
respons
virusspecif
cell
isol
peripher
blood
patient
appear
lost
abil
prolifer
produc
cytokin
interleukin
il
addit
cell
display
reduc
cytotox
absenc
preexist
defect
adapt
immun
immunosuppress
associ
malnutrit
human
immunodefici
viru
hiv
coinfect
renal
failur
cell
dysfunct
attribut
high
level
persist
viral
antigen
addit
factor
influenc
function
capac
cell
pool
activ
stimul
helper
cell
cell
involv
either
directli
activ
dendrit
cell
dc
cell
via
costimul
indirectli
support
b
cell
cell
respons
secret
cytokin
mous
model
lymphocyt
choriomening
viru
lcmv
induc
hepat
cell
function
depend
helper
cell
respons
shown
observ
cell
function
reduc
absenc
cell
moreov
shown
nonhuman
primat
model
hcv
infect
protect
cell
immun
may
requir
helper
cell
primari
infect
also
recoveri
time
rechalleng
treatment
acut
infect
pegifn
result
high
rate
viru
clearanc
part
effici
earli
stimul
antihcv
respons
recent
demonstr
chronic
hcvinfect
patient
mild
absent
diseas
circul
memori
cell
recogn
hcv
core
antigen
contrast
sever
diseas
similarli
chronic
hcv
patient
respond
treatment
ifn
also
demonstr
increas
cytokin
profil
persist
viralspecif
respons
respons
weak
absent
nonrespond
regulatori
cell
treg
cell
constitut
peripher
cell
human
known
activ
engag
neg
control
physiolog
patholog
immun
respons
treg
cell
broad
cell
receptor
repertoir
recogn
variou
self
nonself
antigen
suggest
immun
system
employ
treg
cell
maintain
selftoler
suppress
activ
expans
selfreact
lymphocyt
might
otherwis
caus
autoimmun
diseas
control
balanc
initi
downregul
host
immun
respons
vital
mainten
immun
homeostasi
number
studi
suggest
deplet
reduct
treg
cell
lead
enhanc
immun
respons
variou
infecti
pathogen
includ
hcv
higher
proport
treg
cell
found
patient
chronic
hcv
infect
compar
success
treat
andor
healthi
control
vitro
deplet
cell
result
increas
hcvspecif
cell
respons
thu
treg
cell
appear
suppress
effector
respons
virusspecif
cell
patient
chronic
hcv
infect
treg
cell
shown
exert
suppress
activ
number
differ
pathway
product
immunoregulatori
cytokin
propos
major
mechan
treg
cell
mediat
function
treg
cell
suppress
cytokin
describ
literatur
includ
transform
growth
factor
tgf
molecul
shown
play
key
role
suppress
activ
treg
cell
recent
other
identifi
fibrinogenlik
protein
put
effector
gene
treg
cell
regulatori
cell
subset
includ
low
cell
cell
intestin
doubl
neg
dn
cell
also
known
fibroleukin
first
clone
cytotox
lymphocyt
classifi
member
fibrinogen
superfamili
due
homolog
fibrinogen
chain
gene
local
chromosom
human
mice
respect
compos
two
exon
separ
one
intron
promot
contain
ci
element
consensu
sequenc
bind
variou
transcript
factor
includ
et
ikaro
cebp
gene
encod
protein
amino
acid
mice
amino
acid
human
deduc
protein
sequenc
contain
predict
signal
peptid
five
nlink
glycosyl
site
conserv
cystein
residu
nonreduc
condit
molecular
mass
protein
kda
reduc
condit
kda
indic
natur
state
form
tetramer
complex
base
sequenc
structur
analysi
predict
encod
protein
compos
two
major
region
ntermin
domain
carboxylterminu
ntermin
domain
propos
linear
conform
due
presenc
region
sever
conserv
cystein
residu
promot
coiledcoil
format
carboxylterminu
consist
highli
conserv
globular
domain
known
fibrinogenrel
domain
fred
characterist
fibrinogenrel
protein
superfamili
overal
ident
mous
human
within
fred
domain
two
protein
share
homolog
macrophag
endotheli
cell
primarili
express
membraneassoci
protein
figur
prothrombinas
activ
abil
gener
thrombin
directli
prothrombin
combin
sitedirect
mutagenesi
product
truncat
protein
shown
serin
residu
ntermin
domain
critic
prothrombinas
activ
prothrombinas
activ
implic
pathogenesi
variou
human
experiment
model
diseas
includ
viral
hepat
xenoand
allotransplant
reject
fetal
loss
syndrom
secret
regulatori
cell
figur
inhibit
dc
matur
function
induc
b
cell
apoptosi
ctermin
globular
portion
suggest
account
immunomodulatori
function
molecul
exert
regulatori
activ
bind
fc
gamma
receptor
express
differenti
antigenpres
cell
includ
monocyt
macrophag
dc
b
cell
endotheli
cell
regulatori
activ
implic
inhibit
allograft
reject
autoimmun
pathogenesi
experiment
human
viral
infect
includ
patient
hiv
sever
acut
respiratori
syndrom
sar
hepat
b
viru
although
prothrombinas
activ
membraneassoci
express
macrophag
endotheli
cell
well
establish
mani
studi
exact
role
cellsecret
remain
undefin
recent
studi
group
laboratori
suggest
might
import
regul
adapt
immun
respons
would
consist
observ
member
fibrinogenrel
superfamili
contain
fred
domain
previous
shown
immunoregulatori
activ
addit
role
coagul
member
fibrinogenrel
superfamili
includ
tenascin
inhibit
cell
activ
respons
alloantigen
con
fibrinogen
abil
trigger
seri
intracellular
signal
event
cellular
respons
upon
interact
integrin
angiopoietin
ficolin
also
shown
abil
regul
host
immun
respons
clinic
studi
also
suggest
role
immunoregul
kohno
et
al
show
express
downregul
patient
acut
chronic
adult
cell
leukemialymphoma
patient
acut
chronic
hepat
b
infect
report
express
high
level
liver
addit
genom
analysi
reveal
polymorph
gene
patient
suscept
sar
sever
periodont
lastli
recent
studi
demonstr
abund
level
protein
liver
patient
hepatocellular
carcinoma
collect
clinic
data
support
hypothesi
might
involv
regul
immuni
role
regul
adapt
immun
respons
first
shown
chan
et
al
studi
molecular
function
properti
protein
vitro
recombin
gener
baculoviru
express
system
inhibit
prolifer
cell
respons
stimul
antibodi
con
alloantigen
inhibitori
effect
cell
mediat
suppress
dc
matur
character
inhibit
nuclear
factor
kappa
beta
transloc
nucleu
result
downregul
major
histocompat
complex
mhc
class
ii
molecul
suppress
effect
abrog
specif
antibodi
direct
ctermin
domain
strongli
suggest
carboxyl
fred
region
account
regulatori
activ
molecul
recombin
protein
also
polar
allogen
cell
respons
toward
cytokin
profil
increas
product
decreas
secret
cytokin
includ
anoth
studi
shown
absenc
associ
acceler
cellular
reject
xenotranspl
model
number
group
recent
report
regulatori
cell
increas
gene
transcript
detect
microarray
gene
analysi
herman
et
al
first
report
increas
transcript
treg
cell
isol
pancrea
diabet
mice
subsequ
studi
rudenski
et
al
also
detect
high
express
treg
cell
isol
wildtyp
gfp
mice
mice
upregul
express
observ
treg
cell
mice
treat
recombin
hour
rudenski
colleagu
show
posit
correl
express
howev
express
direct
control
addit
treg
cell
subset
regulatori
cell
also
found
express
high
level
recent
report
show
regulatori
cell
intestin
mice
overexpress
suggest
play
role
function
cell
laboratori
detect
high
product
protein
mrna
primari
clone
dn
regulatori
cell
interestingli
high
level
produc
function
clone
dn
cell
undetect
nonfunct
dn
cell
clone
furthermor
increas
express
primari
dn
cell
correl
suppress
activ
vitro
final
anegon
et
al
found
increas
express
low
regulatori
cell
mediat
allograft
toler
rat
transplant
model
person
commun
role
differ
type
regulatori
cell
current
evalu
agreement
previou
studi
high
level
transcript
detect
treg
cell
realtim
polymeras
chain
reaction
pcr
mice
increas
number
percentag
treg
cell
found
greater
express
compar
treg
cell
howev
suppress
activ
treg
cell
significantli
impair
furthermor
antibodi
complet
inhibit
activ
treg
cell
vitro
strongli
support
content
express
account
suppress
activ
treg
cell
consist
contribut
treg
cell
activ
target
delet
gene
led
increas
immun
reactiv
dc
cell
b
cell
develop
autoimmun
glomerulonephr
age
mice
laboratori
extens
studi
role
prothrombinas
model
fulmin
hepat
caus
murin
hepat
viru
strain
suscept
strain
mice
develop
fatal
hepat
character
intravascular
thrombosi
hepatocellular
necrosi
resist
strain
mice
surviv
clear
viru
within
day
infect
sever
line
evid
suggest
induct
contribut
lethal
hepat
first
suscept
balbcj
semisuscept
mice
induct
interest
balbcj
mice
express
high
level
uniformli
die
liver
failur
wherea
surviv
mice
express
moder
level
develop
chronic
hepat
figur
refer
contrast
resist
aj
mice
fail
produc
follow
infect
either
vivo
vitro
surviv
clear
viru
figur
refer
second
treatment
suscept
mice
monoclon
antibodi
prevent
thrombosi
hepat
necrosi
lethal
infect
final
target
delet
render
mice
larg
resist
molecular
level
defin
activ
serin
site
requir
phospholipid
prothrombinas
activ
membraneassoci
demonstr
transcript
regul
nucleocapsid
protein
n
strain
mhv
caus
lethal
diseas
shown
mechan
lack
transcript
resist
aj
mice
alter
phosphoryl
signal
transduc
activ
transcript
stat
isoform
recent
develop
enzymelink
immunosorb
assay
elisa
measur
secret
murin
plasma
assay
use
analyz
plasma
sampl
infect
suscept
resist
mice
daili
time
infect
day
postinfect
studi
plasma
level
correl
diseas
progress
mice
express
markedli
elev
level
time
correl
increas
number
treg
cell
wherea
resist
mice
signific
increas
level
treg
cell
moreov
adopt
transfer
treg
cell
resist
mice
increas
mortal
follow
infect
demonstr
import
effector
treg
cell
experiment
viral
hepat
data
collect
suggest
disturb
treg
cell
activ
number
may
import
pathogenesi
viral
induc
liver
injuri
monitor
level
may
use
predict
outcom
infect
develop
sensit
reproduc
elisa
measur
plasma
sampl
human
establish
baselin
level
healthi
control
use
plasma
sampl
healthi
volunt
test
two
separ
occas
plasma
level
compar
patient
chronic
hcv
infect
well
patient
nonvir
relat
liver
diseas
alcoholinduc
liver
diseas
data
shown
figur
suggest
patient
chronic
hcv
infect
level
plasma
significantli
higher
patient
alcohol
liver
diseas
patient
sustain
viral
respons
antivir
treatment
healthi
control
figur
data
demonstr
hcv
patient
clear
viru
follow
antivir
therapi
mean
plasma
level
patient
chronic
hcv
infect
ten
ml
heparin
blood
collect
patient
chronic
hcv
infect
receiv
antivir
therapi
mean
plasma
level
patient
compar
healthi
control
patient
inact
alcohol
cirrhosi
patient
chronic
hcv
clear
viru
follow
success
antivir
therapi
sustain
virolog
respond
svr
mean
plasma
level
significantli
higher
patient
chronic
hcv
infect
ngml
n
compar
healthi
control
ngml
n
patient
alcohol
cirrhosi
ngml
n
patient
svr
ngml
n
develop
svr
level
return
level
seen
normal
healthi
control
furthermor
result
show
presenc
liver
diseas
alon
correl
plasma
level
sinc
patient
alcohol
cirrhosi
level
compar
healthi
control
taken
togeth
preliminari
result
indic
level
may
use
biomark
diseas
progress
respons
therapi
patient
hcv
infect
preliminari
data
also
demonstr
signific
differ
plasma
level
hcv
patient
genotyp
compar
genotyp
patient
versu
ngml
data
date
suggest
patient
high
level
plasma
ngml
vigor
form
hcv
higher
probabl
nonrespond
antivir
therapi
wherea
patient
level
ngml
like
respond
antivir
treatment
demonstr
figur
show
timecours
level
two
repres
patient
chronic
hcv
infect
treat
antivir
therapi
patient
respond
week
therapi
pegyl
interferon
ribavirin
plasma
level
patient
high
prior
initi
therapi
ngml
remain
high
throughout
treatment
month
posttreat
contrast
patient
level
less
ngml
prior
initi
treatment
level
fell
within
week
therapi
level
seen
healthi
control
level
remain
low
complet
therapi
also
preliminari
patholog
evid
interplay
treg
cell
patient
hcv
infect
figur
show
coexpress
membran
cytoplasm
nuclear
master
transcript
factor
treg
cell
inflammatori
cell
liver
patient
chronic
hcv
infect
preliminari
studi
found
patient
high
level
explant
liver
much
like
rapid
aggress
recurr
hcv
respond
poorli
treatment
exampl
differ
degre
express
explant
liver
two
patient
correl
posttranspl
clinic
cours
illustr
figur
panel
show
chronic
hcv
patient
mani
cell
brown
cell
explant
develop
aggress
recurr
diseas
respond
treatment
panel
b
show
anoth
chronic
hcv
patient
scatter
cell
brown
cell
explant
liver
requir
treatment
recurr
hcv
infect
base
upon
data
collect
date
shown
integr
innat
adapt
immun
respons
surpris
molecul
conserv
evolut
singlecel
organ
ameba
higher
primat
propos
mechanist
model
exert
immunoregulatori
effect
figur
figur
show
immunohistochemistri
stain
brown
membran
cytoplasm
blue
nuclear
explant
liver
hcv
patient
lymphocyt
arrow
coexpress
figur
increas
express
explant
liver
correl
sever
recurr
hcv
infect
chronic
hcv
patient
mani
cell
brown
cell
explant
develop
aggress
recurr
diseas
respond
treatment
b
chronic
hcv
patient
scatter
cell
brown
cell
explant
requir
treatment
recurr
hcv
infect
stain
perform
standard
immunohistochemistri
use
monoclon
antibodi
horseradish
immunoperoxidas
method
magnif
treg
cell
secret
bind
inhibitori
receptor
express
dc
bind
downregul
immun
activ
dc
indic
inhibit
express
matur
marker
mhcii
suppress
effect
dc
shown
mediat
inhibit
nuclear
transloc
dc
expos
would
therefor
less
effect
induc
prolifer
effector
function
helper
cytotox
lymphocyt
suppress
helper
cell
activ
dc
matur
could
lead
indirectli
inhibit
tdepend
tindepend
b
cell
respons
respect
demonstr
vitro
studi
also
directli
induc
apoptosi
b
cell
upon
bind
inhibitori
receptor
known
express
b
cell
indirect
direct
suppress
activ
result
inhibit
immun
respons
hcv
lead
viral
persist
chronic
infect
hcv
infect
major
world
health
problem
lead
caus
hcc
worldwid
disturb
treg
cell
function
number
shown
contribut
failur
clearanc
hcv
develop
chronic
hepat
shown
import
effector
molecul
treg
cell
demonstr
play
key
role
pathogenesi
experiment
human
viral
hepat
measur
level
plasma
patient
appear
predict
cours
hcv
diseas
respons
antivir
therapi
biomark
may
becom
import
diagnost
reagent
manag
hcv
patient
furthermor
studi
show
inhibit
improv
outcom
experiment
hepat
thu
provid
impetu
gener
reagent
inhibit
patient
acut
chronic
hepat
b
c
viru
infect
either
alon
combin
present
antivir
agent
express
shown
associ
diseas
includ
hiv
sar
cancer
measur
level
develop
reagent
interfer
may
even
broader
applic
